标题
A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations
作者
关键词
-
出版物
Diagnostics
Volume 10, Issue 2, Pages 114
出版商
MDPI AG
发表日期
2020-02-20
DOI
10.3390/diagnostics10020114
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives
- (2020) Carlo Genova et al. Expert Review of Respiratory Medicine
- On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation
- (2019) Benjamin P Brown et al. CLINICAL CANCER RESEARCH
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- (2019) Natasha B. Leighl et al. CLINICAL CANCER RESEARCH
- Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays
- (2019) Xi‑Wen Jiang et al. Molecular Medicine Reports
- Liquid biopsy tracking of lung tumor evolutions over time
- (2019) Alessandro Russo et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
- (2019) Aaron C. Tan et al. LUNG CANCER
- A CRISPR Test for Detection of Circulating Nuclei Acids
- (2019) Jen-Hui Tsou et al. Translational Oncology
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
- (2018) Neal I. Lindeman et al. Journal of Thoracic Oncology
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
- (2018) Janice S. Chen et al. SCIENCE
- Next-generation diagnostics with CRISPR
- (2018) Daniel S. Chertow SCIENCE
- Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6
- (2018) Jonathan S. Gootenberg et al. SCIENCE
- SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
- (2018) Nathan A. Pennell et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA targeting with CRISPR–Cas13
- (2017) Omar O. Abudayyeh et al. NATURE
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting
- (2012) K. Goto et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search